SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard Hoffman who wrote (988)6/12/1997 2:21:00 AM
From: Roger Cranwill   of 1762
 
I didn't actually want to come out and SAY that, but I've always felt that C2B8 would eventually become the regimen of choice-another point brought up at the meeting-at this time, THERE IS NO PRODUCT ON THE MARKET THAT IS APPROVED BY THE FDA FOR USE IN NON-HODGKIN'S LYMPHOMA...in other words, a physician can't find a package insert for any drug that lists a suggested regimen for treatment of the disease! When C2B8 is approved, it will be the ONLY product with proper labeling to be indicated for Non-Hodgkin's lymphoma-think of the legal ramifications of that statement-what regimen would be able to be justified in a court of law (just for the sake of arguement). BTW, this isn't just something I made up, or think I might know-this was actually stated at the meeting (the part about legal ramifications is my own, but the package labeling was brought up by the CEO). Roger
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News